Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + RIF + venetoclax for newly diagnosed acute promyelocytic leukemia
ChiCTR2200066592Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, tretinoin and Compound Huangdai Tablet in Acute promyelocytic leukaemia (APL), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Complete molecular remission rate and Cumulative incidence of relapse. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
venetoclaxtretinoinCompound Huangdai Tablet
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2200066592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066592.